[Expression and Clinical Significance of lncRNA NCK1-AS1 in Acute Myeloid Leukemia].

Q4 Medicine

中国实验血液学杂志 Pub Date : 2025-04-01 DOI:10.19746/j.cnki.issn.1009-2137.2025.02.007

Chen Cheng, Zi-Jun Xu, Pei-Hui Xia, Xiang-Mei Wen, Ji-Chun Ma, Yu Gu, Di Yu, Jun Qian, Jiang Lin

{"title":"[Expression and Clinical Significance of lncRNA NCK1-AS1 in Acute Myeloid Leukemia].","authors":"Chen Cheng, Zi-Jun Xu, Pei-Hui Xia, Xiang-Mei Wen, Ji-Chun Ma, Yu Gu, Di Yu, Jun Qian, Jiang Lin","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.007","DOIUrl":null,"url":null,"abstract":"Objective: To detect and analyze the expression and clinical significance of long non-coding RNA tyrosine kinase non-catalytic region adaptor protein 1-antisense RNA1 (NCK1-AS1) in patients with acute myeloid leukemia (AML).Methods: 89 AML patients and 23 healthy controls were included from the People's Hospital Affiliated to Jiangsu University. Real-time quantitative polymerase chain reaction (RT-qPCR) was used to detect the expression levels of NCK1-AS1 and NCK1 in bone marrow samples. The relationship between the expression of NCK1-AS1 and the clinical characteristics of patients were analyzed, as well as the correlation between NCK1-AS1 and NCK1.Results: The expression level of NCK1-AS1 in all AML, non-M3 AML and cytogenetically normal AML (CN-AML) patients was significantly higher than that in the control group (P < 0.01, P < 0.05, P < 0.01, respectively). In non-M3 AML, patients with high NCK1-AS1 expression had a significantly lower hemoglobin level than those with low NCK1-AS1 expression (P =0.036), furthermore, NCK1-AS1 high patients had shorter overall survival than NCK1-AS1low patients (P =0.0378). Multivariate analysis showed that NCK1-AS1 expression was an independent adverse factor in patients with non-M3 AML ( HR =2.392, 95% CI :1.089-5.255, P =0.030). In addition, NCK1 expression was also significantly upregulated in all AML, non-M3 AML and CN-AML patients compared with controls (P < 0.01, P < 0.01, P < 0.001, respectively). There was a certain correlation between NCK1-AS1 and NCK1 expression (r =0.37, P =0.0058).Conclusion: High expression of NCK1-AS1 in AML indicates poor prognosis of AML patients.","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"352-358"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国实验血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To detect and analyze the expression and clinical significance of long non-coding RNA tyrosine kinase non-catalytic region adaptor protein 1-antisense RNA1 (NCK1-AS1) in patients with acute myeloid leukemia (AML).

Methods: 89 AML patients and 23 healthy controls were included from the People's Hospital Affiliated to Jiangsu University. Real-time quantitative polymerase chain reaction (RT-qPCR) was used to detect the expression levels of NCK1-AS1 and NCK1 in bone marrow samples. The relationship between the expression of NCK1-AS1 and the clinical characteristics of patients were analyzed, as well as the correlation between NCK1-AS1 and NCK1.

Results: The expression level of NCK1-AS1 in all AML, non-M3 AML and cytogenetically normal AML (CN-AML) patients was significantly higher than that in the control group (P < 0.01, P < 0.05, P < 0.01, respectively). In non-M3 AML, patients with high NCK1-AS1 expression had a significantly lower hemoglobin level than those with low NCK1-AS1 expression (P =0.036), furthermore, NCK1-AS1 ^high patients had shorter overall survival than NCK1-AS1^low patients (P =0.0378). Multivariate analysis showed that NCK1-AS1 expression was an independent adverse factor in patients with non-M3 AML ( HR =2.392, 95% CI :1.089-5.255, P =0.030). In addition, NCK1 expression was also significantly upregulated in all AML, non-M3 AML and CN-AML patients compared with controls (P < 0.01, P < 0.01, P < 0.001, respectively). There was a certain correlation between NCK1-AS1 and NCK1 expression (r =0.37, P =0.0058).

Conclusion: High expression of NCK1-AS1 in AML indicates poor prognosis of AML patients.

查看原文本刊更多论文

[lncRNA NCK1-AS1在急性髓系白血病中的表达及临床意义]。

目的：检测并分析长链非编码RNA酪氨酸激酶非催化区接头蛋白1-反义RNA1 （NCK1-AS1）在急性髓性白血病（AML）患者中的表达及临床意义。方法：选取江苏大学附属人民医院急性髓系白血病患者89例，健康对照23例。采用实时定量聚合酶链反应（RT-qPCR）检测NCK1- as1和NCK1在骨髓样品中的表达水平。分析NCK1- as1表达与患者临床特征的关系，以及NCK1- as1与NCK1的相关性。结果：NCK1-AS1在所有AML、非m3 AML和细胞遗传学正常AML （CN-AML）患者中的表达水平均显著高于对照组（P < 0.01、P < 0.05、P < 0.01）。在非m3 AML中，NCK1-AS1高表达患者的血红蛋白水平显著低于NCK1-AS1低表达患者（P =0.036），且NCK1-AS1高表达患者的总生存期短于NCK1-AS1low患者（P =0.0378）。多因素分析显示，NCK1-AS1表达是非m3 AML患者的独立不良因素（HR =2.392, 95% CI:1.089 ~ 5.255, P =0.030）。此外，与对照组相比，所有AML、非m3 AML和CN-AML患者的NCK1表达均显著上调（P < 0.01, P < 0.01, P < 0.001）。NCK1- as1与NCK1表达有一定的相关性（r =0.37, P =0.0058）。结论：NCK1-AS1在AML中高表达预示着AML患者预后不良。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊